B.S. Biology, Yarmouk University, Jordan.
M.S. Biotechnology, Middle East Technical University, Turkey.
Ph.D. Microbiology and Biochemistry, University of Georgia, Athens, GA
Post doc Mayo Clinic School of Medicine, Mayo Clinic Cancer Center, Jacksonville, Florida,
Microbiology, Protein Biochemistry, Cancer Biology, Molecular and Structural Biology
In graduate school at University of Georgia, Dr. Salameh worked on exploring, purification, cloning and characterization of industrial enzymes from novel thermophilic anaerobic bacteria for academic and industrial purposes. In 2006, Dr. Salameh accepted a post doctorate position at Mayo Clinic Cancer Center, School of Medicine. He explored the role of serine proteases on cancer progression and development.
He is now the director of bioscience at Gwinnett Tech, his research focuses on the molecular interactions involved in inhibiting one of the unusual proteinases named mesotrypsin/PRSS3 by employing techniques of structural biology, cell biology, and enzymology. Mesotrypsin is a highly unusual trypsin in that it is remarkably resistant to inhibition by proteinaceous trypsin inhibitors, and rapidly degrades them as substrates. Mesotrypsin expression has been strongly associated with the progression and metastasis in pancreatic and prostates cancers. Our research goal is to develop mesotrypsin inhibitors with improved selectivity and stability toward mesotrypsin, and to evaluate mesotrypsin inhibitors for therapeutic efficacy in models of prostate cancer progression.
1- Szabó A, Salameh MA, Ludwig M, Radisky ES, Sahin-Tóth M. 2014. Tyrosine sulfation of human trypsin steers S2′ subsite selectivity towards basic amino acids. PLOS ONE. 9, DOI: 10.1371/journal.pone.0102063.
2- Salameh, M. A. and Radiskey E. S. 2013. Biochemical and structural insights into mesotrypsin: an unusual human trypsin. Int. J. Biochem. Mol. Biol. 4, 129-139.
3- Salameh, M. A., Soares, A. S. and Radisky E. S. 2012. Presence versus absence of hydrogen bond donor Tyr-39 influences interactions of cationic trypsin and mesotrypsin with protein protease inhibitors. Protein Sci. 21, 1103-1112.
4- Hockla A, Miller E, Salameh M. A., Copland J. A., Radisky D. C., Radisky E. S. 2012. PRSS3/mesotrypsin is a therapeutic target for metastatic prostate cancer. Mol. Cancer Res. 10, 1555-1566.
5- Salameh, M. A., Soares A. S., Hockla, A., Radisky, D.C. and E.S. Radisky. 2011. The P2` residue is a key determinant of mesotrypsin specificity: Engineering a high affinity inhibitor with anticancer activity. Biochemical J. 440(1):95-105.
6- Salameh, M. A., Robinson, J.L., Navaneetham, D., Sinha, D., Madden, B. J., Walsh, P. N., and E.S. Radisky. 2010. The amyloid precursor protein protease inhibitor nexin2 kunitz Inhibitor Domain is highly specific substrate of mesotrypsin. J. Biol. Chem. 285, 1939-1949.
7- Salameh, M. A., Soares, A S., Navaneetham, D., Sinha, D., Walsh, P. N., and E.S. Radisky. 2010. Determinants of affinity and proteolytic stability in interactions of kunitz family protease inhibitors with mesotrypsin. J. Biol. Chem. 285, 36884-36896.
8- Salameh M. A. and J. Wiegel. 2010. Effects of Detergents on Activity, Thermostability and Aggregation of Two Alkalithermophilic Lipases from Thermosyntropha lipolytica. The Open Biochem. J. 5, 22-28.
9- Salameh, M. A., and J. Wiegel J. 2009. Synthesis of fatty acid esters and diacylglycerols at elevated temperatures by alkalithermophilic lipases from Thermosyntropha lipolytica. J. Ind. Microbiol. Biotechnol. 36, 1281-7.
10- Salameh, M. A., Soares, A. S., Hockla, A., and E. S. Radisky. 2008. Structural basis for accelerated cleavage of bovine pancreatic trypsin inhibitor (BPTI) by human mesotrypsin. J. Biol. Chem. 283, 4115-4123.
11- Salameh, M. and J. Wiegel. 2007. Lipases from extremophiles and potential for industrial applications. Adv. Appl. Microbiol. 61, 253-283.
12- Salameh, M. A. and J. Wiegel. 2007. Purification and characterization of two highly thermophilic alkaline lipases from Thermosyntropha lipolytica. Appl. Environ. Microbiol. 73, 7725-7731.
13- Salameh, M. A., Soares A. S and E.S. Radisky. Selection of potent mesotrypsin inhibitor from a phage display library of bovine pancreatic trypsin inhibitor (BPTI). submitted.
14- Palermino, K., Goodroe, J., Chancer, K., Bonani, Y., Bryant, A., Wood, B., and M. Salameh. 2017. Engineering a strong mesotrypsin inhibitor with high selectivity. J. biol. Chem. submitted.